Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma.

The Journal of urology - 1 Oct 1999

Luo Y, Chen X, Han R, Chorev M, Dewolf W C, O'Donnell M A

Abstract excerpt

PURPOSE: To establish an experimental mouse model for bladder cancer immunotherapy using mutated ras as a target. MATERIALS AND METHODS: A tumorigenic mouse bladder transitional cell carcinoma (TCC) line MB49 (C57BL/6 origin) was analyzed for its c-ras gene status by DNA cloning and sequencing. Aberrant expression of the ras gene was measured with Western blotting. 13-mer peptides corresponding to residues 5 to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Transitional Cell
Share to CD4-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD8-Positive T-Lymphocytes

Share to Cytokines

Share to Genes, ras

Share to Immunotherapy

Share to Peptides

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 10492248

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma.PMID 10492248Read ↗

Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.Semantic proximity Read ↗

Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein.Semantic proximity Read ↗

MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.Semantic proximity Read ↗

T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.Semantic proximity Read ↗

Subunit peptide cancer vaccines targeting activating mutations of the p21 ras proto-oncogene.Semantic proximity Read ↗

Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes.Semantic proximity Read ↗

Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins.Semantic proximity Read ↗

N-methylnitrosourea-induced Ki-ras codon 12 mutations: early events in mouse thymic lymphomas.Semantic proximity Read ↗

p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp).Semantic proximity Read ↗

Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation.Semantic proximity Read ↗

IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer.Semantic proximity Read ↗

A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.